LYNPARZA® (olaparib) receives approval in Japan for treatment of advanced ovarian cancer
AstraZeneca and Merck announced the Japanese Ministry of Health, Labour and Welfare has approved LYNPARZA® (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status. January 19, 2018